Seung Tae Kim, MD

Seung Tae Kim, MD
 

Division of Hematology Oncology
Department of Medicine
Samsung Medical Center
Sungkyunkwan University School of Medicine
Seoul, Korea

How are you using NGS and comprehensive genomic profiling in South Korea, and in which cancer subtypes are you using NGS to identify actionable molecular targets and targeted treatment strategies? (Korean) Video

How are you using NGS and comprehensive genomic profiling in South Korea, and in which cancer subtypes are you using NGS to identify actionable molecular targets and targeted treatment strategies? (Korean)

How are you using NGS and comprehensive genomic profiling in South Korea, and in which cancer subtypes are you using NGS to identify actionable molecular targets and targeted treatment strategies?
Seung Tae Kim, MD

Seung Tae Kim, MD

What is the role of NGS for the assessment of gastric and colorectal cancer? (Korean) Video

What is the role of NGS for the assessment of gastric and colorectal cancer? (Korean)

What is the role of NGS for the assessment of gastric and colorectal cancer?
Seung Tae Kim, MD

Seung Tae Kim, MD

In what subtypes of cancer have we validated the efficacy of comprehensive NGS screening for improving outcomes by aligning molecular targets with appropriate therapies and predictive biomarkers of efficacy? (Korean) Video

In what subtypes of cancer have we validated the efficacy of comprehensive NGS screening for improving outcomes by aligning molecular targets with appropriate therapies and predictive biomarkers of efficacy? (Korean)

In what subtypes of cancer have we validated the efficacy of comprehensive NGS screening for improving outcomes by aligning molecular targets with appropriate therapies and predictive biomarkers of efficacy?
Seung Tae Kim, MD

Seung Tae Kim, MD

What do you recommend regarding the timing for NGS-based genomic profiling? Do you believe it should be used early in the neoadjuvant setting or only in advanced, resistant, or metastatic disease? (Korean) Video

What do you recommend regarding the timing for NGS-based genomic profiling? Do you believe it should be used early in the neoadjuvant setting or only in advanced, resistant, or metastatic disease? (Korean)

What is your recommendation regarding the timing of use for NGS-based genomic profiling? Do you believe it should be used early in the neoadjuvant setting or only in advanced, resistant, or metastatic disease?
Seung Tae Kim, MD

Seung Tae Kim, MD